Omalizumab therapy for bullous pemphigoid

Journal of the American Academy of Dermatology

Volumn 71, Issue 3, 2014, Pages 468-474

  Yu, Kenneth K ^a   Crew, Ashley B ^a   Messingham, Kelly A N ^b   Fairley, Janet A ^b,c   Woodley, David T ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

autoimmunity; bullous pemphigoid; IgE; omalizumab; pruritus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; DOXYCYCLINE; FEXOFENADINE; HYDROXYZINE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OMALIZUMAB; PREDNISONE; RITUXIMAB; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLISTER; BULLOUS PEMPHIGOID; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; MONOTHERAPY; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; TREATMENT DURATION; VERY ELDERLY; CASE REPORT; DRUG EFFECTS; IMMUNOLOGY; PEMPHIGOID, BULLOUS;

AGED; AGED, 80 AND OVER; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOGLOBULIN E; PEMPHIGOID, BULLOUS;

EID: 84906303915     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.04.053     Document Type: Article

References (21)

1. J.R. Stanley, P. Hawley-Nelson, S.H. Yuspa, E.M. Shevach, and S.I. Katz Characterizatrion of bullous pemphigoid antigen: a unique basement membrane zone protein of stratified squamous epithelia Cell 24 1981 897 903
2. R.S. Labib, G.J. Anhalt, H.P. Patel, D.F. Mutasim, and L.A. Diaz Molecular heterogeneity of the bulllous pemphigoid antigens as detected by immunoblotting J Immunol 136 1986 1231 1235
3. C.E. Arbesman, J.I. Wypych, R.E. Reisman, and E.H. Beutner IgE levels in sera of patients with pemphigus or bullous pemphigoid Arch Dermatol 110 1974 378 381
4. M. Bowszyc-Dmochowska, W. Silny, and M. Dmochowski Detection of IgG4 deposits using a single-step direct immunofluorescence on natrium chloride-separated skin and elevated levels of serum total IgE in active bullous pemphigoid J Invest Dermatol 114 2000 804a
5. O.G. Dimson, G.J. Giudice, C.L. Fu, F. Van den Bergh, S.J. Warren, and M.M. Janson et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid J Invest Dermatol 120 2003 784 788
6. E. Delaporte, A. Dubost-Brama, R. Ghohestani, J.F. Nicolas, J.L. Neyrinck, and H. Bergoend et al. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid J Immunol 157 1996 3642 3647
7. S. Christophoridis, L. Budinger, L. Borradori, T. Hunziker, H.F. Merk, and M. Hertl IgG, IgA, and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis Br J Dermatol 143 2000 349 355
8. T.T. Provost, and T.B. Tomasi Jr. Immunopathology of bullous pemphigoid: basement membrane deposition of IgE, alternate pathway components and fibrin Clin Exp Immunol 18 1974 193 200
9. V.A. Venning, K. Taghipour, M.F. Mohd Mustapa, A.S. Highet, and G. Kirtschig British Association of Dermatologists' guidelines for the management of bullous pemphigoid Br J Dermatol 167 2012 1200 1214
10. S. Holgate, N. Smith, M. Massanari, and P. Jimenez Effects of omalizumab on markers of inflammation in patients with allergic asthma Allergy 64 2009 1728 1736
11. J.A. Fairley, C.L. Baum, D.S. Brandt, and K.A. Messingham Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab J Allergy Clin Immunol 123 2009 704 705
12. V.A. London, G.H. Kim, J.A. Fairley, and D.T. Woodley Successful treatment of bullous pemphigoid with omalizumab Arch Dermatol 148 2012 1241 1243
13. K.A.N. Messingham, M.H. Noe, M.A. Chapman, G.J. Giudice, and J.A. Fairley A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid J Immunol Methods 346 2009 18 25
14. H. Milgrom, R.B. Fick Jr., J.Q. Su, J.D. Reimann, R.K. Bush, and M.L. Watrous et al. Treatment of allergic asthma with monoclonal anti-IgE antibody N Engl J Med 341 1999 1966 1973
15. R. Djukanovic, S.J. Wilson, M. Kraft, N.N. Jarjour, M. Steel, and K.F. Chung et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma Am J Respir Crit Care Med 170 2004 583 593
16. W. Busse, R. Buhl, C. Fernandez-Vidaurre, M. Blogg, J. Zhu, and M.D. Eisner et al. Omalizumab and the risk of malignancy: results from a pooled analysis J Allergy Clin Immunol 129 2012 983 989
17. J. Corren, G. Shapiro, J. Reimann, Y. Deniz, D. Wong, and A. Adelman et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy J Allergy Clin Immunol 121 2008 506 511
18. J.J. Zone, T. Taylor, C. Hull, L. Schmidt, and L. Meyer IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice J Invest Dermatol 127 2007 1167 1174
19. J.A. Fairley, C.T. Burnett, C.-L. Fu, D.L. Larson, M.G. Fleming, and G.J. Giudice A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice J Invest Dermatol 127 2007 2605 2611
20. B.U. Wintroub, M.C. Mihm Jr., E.J. Goetzl, N.A. Soter, and K.F. Austen Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid N Engl J Med 298 1978 417 421
21. K.D. Stone, C. Prussin, and D.D. Metcalfe IgE, mast cells, basophils, and eosinophils J Allergy Clin Immunol 125 2010 S73 S80